Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 91 AL 105

A clinical perspective: anti tau's treatment in Alzheimer's disease

Fuentes P, Catalan J.

Curr Alzheimer Res. 2011 Sep;8(6):686-8. doi: 10.2174/156720511796717221.

Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies

Navarrete LP, Pérez P, Morales I, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):678-85. doi: 10.2174/156720511796717122.

Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers

Calon F.

Curr Alzheimer Res. 2011 Aug;8(5):470-8. doi: 10.2174/156720511796391881.

Nutritional approaches to modulate oxidative stress in Alzheimer's disease

Pocernich CB, Lange ML, Sultana R, Butterfield DA.

Curr Alzheimer Res. 2011 Aug;8(5):452-69. doi: 10.2174/156720511796391908.

The ability of tolfenamic acid to penetrate the brain: a model for testing the brain disposition of candidate Alzheimer's drugs using multiple platforms

Subaiea GM, Alansi BH, Serra DA, Alwan M, Zawia NH.

Curr Alzheimer Res. 2011 Dec;8(8):860-7. doi: 10.2174/156720511798192691.

Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial

Scarpini E, Bruno G, Zappalà G, Adami M, Richarz U, Gaudig M, Jacobs A, Schäuble B.

J Alzheimers Dis. 2011;26(2):211-20. doi: 10.3233/JAD-2011-110134.

Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease

Sodhi RK, Singh N, Jaggi AS.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Aug;384(2):115-24. doi: 10.1007/s00210-011-0654-6. Epub 2011 May 24.

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A.

BMC Neurol. 2011 May 25;11:57. doi: 10.1186/1471-2377-11-57.

Combined administration of D-galactose and aluminium induces Alzheimer-like lesions in brain

Xiao F, Li XG, Zhang XY, Hou JD, Lin LF, Gao Q, Luo HM.

Neurosci Bull. 2011 Jun;27(3):143-55. doi: 10.1007/s12264-011-1028-2.

Transdermal rivastigmine: management of cutaneous adverse events and review of the literature

Greenspoon J, Herrmann N, Adam DN.

CNS Drugs. 2011 Jul;25(7):575-83. doi: 10.2165/11592230-000000000-00000.

AMP-activated protein kinase: a potential player in Alzheimer's disease

Salminen A, Kaarniranta K, Haapasalo A, Soininen H, Hiltunen M.

J Neurochem. 2011 Aug;118(4):460-74. doi: 10.1111/j.1471-4159.2011.07331.x. Epub 2011 Jun 24.

A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model

Capsoni S, Brandi R, Arisi I, D'Onofrio M, Cattaneo A.

CNS Neurol Disord Drug Targets. 2011 Aug;10(5):635-47. doi: 10.2174/187152711796235032.

Alzheimer's disease: β-amyloid plaque formation in human brain

Seeman P, Seeman N.

Synapse. 2011 Dec;65(12):1289-97. doi: 10.1002/syn.20957.

Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease

Voronkov M, Braithwaite SP, Stock JB.

Future Med Chem. 2011 May;3(7):821-33. doi: 10.4155/fmc.11.47.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias